| Age | Sex | Diagnosis | Karyotype/Mutations | ELN risk score | WHO AML category | De-Novo/secondary AML | WBC at diagnosis | Extramedullary involvement |
---|---|---|---|---|---|---|---|---|---|
P1 | 27 | Female | Jan 2019 | Intermediate | M4 - acute monoblastic/ monocytic leukemia | De novo | 1.24 × 1000/mcl | No | |
P2 | 18 | Female | Dec 2017 | t(8;21) | Favorable | M1- AML without maturation | De novo | 3.05 × 1000/mcl | No |
GR1 | 38 | Male | May 2016 | Normal Karyotype, NPM1mut | Favorable | M2- AML with maturation | De novo | 166 × 1000/mcl | No |
GR2 | 62 | Male | Sep 2018 | Normal Karyotype, NPM1mut | Favorable | M1- AML without maturation | De novo | 6.6 × 1000/mcl | No |
GR3 | 69 | Male | Jan 2017 | Normal Karyotype | Intermediate | M2- AML with maturation | De novo | 11.7 × 1000/mcl | No |
GR4 | 63 | Female | Dec 2010 | Normal Karyotype | Intermediate | M1- AML without maturation | De novo | 4.4 × 1000/mcl | No |
GR5 | 28 | Male | Oct 2013 | t(8;21) | Favorable | M2- AML with maturation | De novo | 25.8 × 1000/mcl | No |